ARGENX VYVGART Phase 3 Trial for Ocular MG Meets Primary Endpoint, Paving Way for Label Expansion

summarizeSummary

ARGENX announced positive Phase 3 results for VYVGART in ocular myasthenia gravis, meeting its primary endpoint and supporting a planned FDA submission for label expansion into this underserved patient population.

check_boxKey Events

• Positive Phase 3 Trial Results

  The ADAPT OCULUS study for VYVGART in ocular myasthenia gravis (oMG) met its primary endpoint (p-value=0.012), showing statistically significant improvement in ocular symptoms for patients treated with VYVGART compared to placebo.

• Significant Symptom Reduction

  Patients treated with VYVGART experienced a marked reduction in key ocular symptoms, including diplopia (double vision) and ptosis (drooping eyelids).

• Planned Regulatory Submission

  The positive results support a planned Supplemental Biologics License Application (sBLA) submission to the U.S. FDA to expand VYVGART's label into oMG, addressing a significant unmet medical need.

• Favorable Safety Profile

  VYVGART was well tolerated in oMG patients, with a safety profile consistent with prior studies and no new safety concerns identified.

auto_awesomeAnalysis

ARGENX SE announced highly positive topline results from its Phase 3 ADAPT OCULUS trial for VYVGART in ocular myasthenia gravis (oMG). The study successfully met its primary endpoint, demonstrating statistically significant improvement in ocular symptoms for patients treated with VYVGART compared to placebo. This outcome is crucial as oMG represents a significant unmet medical need with no currently approved targeted therapies. These results support a planned Supplemental Biologics License Application (sBLA) submission to the FDA, which could significantly expand VYVGART's market reach and solidify ARGENX's leadership in autoimmune disease treatments.